Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Advertisement
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Galmed To Design Phase III NASH Trial With FDA After Strong Aramchol Data

The Israel-based biopharma company said a Phase IIb trial of its oral treatment of non-alcoholic steatohepatitis hit the necessary endpoints to support a Phase III trial and FDA marketing application.

Clinical Trials Companies

More Change At GSK's Top, With Vaccines Chief Luc Debruyne Set To Say 'Adieu'

The head of GSK's vaccines division, Luc Debruyne, is leaving the company at the end of the year.

Leadership Vaccines

Targovax Adjusts Clinical Pipeline After ASCO Disrupts TG Vaccine Program

Targovax terminates development of TG01 in pancreatic cancer patients after data unveiled at ASCO fundamentally alters development preconditions for its TG vaccine program.

Research and Development Strategies ASCO

Historic Mapping Of Deadly Pathogens Allows PacBio To Showcase Its Platform

PacBio and Wellcome Sanger Institute tell Scrip why they've teamed up to decode genomes of more than 3,000 bacteria, including some of the world's most dangerous, and how it will help fight AMR and bioterrorism.

Platform Technologies Strategy

Novo Nordisk Seen Readying Steps To Offset US Pressures, Including Job Cuts

Novo Nordisk is rumored to be considering laying off up to 3,000 staff and dropping its long-term financial targets due to challenging US market conditions which the group flagged in its first-quarter update in May.

Business Strategies Companies

Oxford BioMedica CEO To Hire More People, Expects More Deals Following Gene Therapy Pact With Axovant

Britain's Oxford BioMedica has signed a $842m deal with US-based Axovant Sciences to commercialize its next generation gene therapy for Parkinson's disease.

Deals Regenerative Medicine
See All
Advertisement
UsernamePublicRestriction

Register